LA
JNCE

Legacy Advisors’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Legacy Advisors’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-500
Closed -$7K – 366
2017
Q2 		$7K Buy
+500
New +$10.7K 0.01% 172

Other funds holding JNCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Legacy Advisors's JNCE Position: Q3 2017 in Review

Legacy Advisors sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2017, closing a stake of 500 shares — an estimated $7K sold.

Legacy Advisors first reported a position in JNCE in Q2 2017 and held it in 1 quarter. The position peaked at $7K in Q2 2017. 76 funds tracked by Wall St. Rank hold JNCE as of Q3 2017.

  • Legacy Advisors reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Legacy Advisors sold 500 Jounce Therapeutics, Inc. Common Stock shares in Q3 2017, an estimated $7K.
  • Legacy Advisors first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2017 and held it in 1 quarter.
  • Legacy Advisors's Jounce Therapeutics, Inc. Common Stock position peaked at $7K in Q2 2017.
  • 76 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2017.

Based on Legacy Advisors's 13F filing for Q3 2017, filed 1 Nov 2017.